

New Concepts and Care for IBD and Liver Disease

MONDAY 29th SEPTEMBER

07:45 Registration, Examination Schools, Oxford

Coffee

08:30 Welcome

S1 Pathogenesis: messages for practice in IBD **Fiona Powrie/Alison Simmons**

08:40 Very early onset IBD Holm Uhlig (Oxford)

09:05 T-cell plasticity: does function change as inflammation progresses? Ahmed Hegazy (Oxford)

09:30 Biomarkers of tomorrow: what hope for today? Oliver Brain (Oxford)

09:55 Inflammation and carcinogenesis: any smoke without fire? Simon Leedham (Oxford)

10:20 *Coffee*

S2 IBD therapy **Satish Keshav/Oliver Brain**

10:50 Have steroids been and gone? Simon Travis (Oxford)

11:10 Who will still be using azathioprine monotherapy in 2015? Peter Irving (London)

11:30 Time for a change: anti-integrin therapy Arthur Kaser (Cambridge)

11:55 Optimising anti-TNF therapy: drug monitoring James Lindsay (London)

12:20 New kids on the block: SMAD7 and friends Giovanni Monteleone (Rome)

12:45 *Lunch*

S3 Managing the manageable in IBD **Adam Bailey/Vipul Jairath**

14:00 Iron deficiency in IBD Tariq Iqbal (Birmingham)

14:20 Vitamin D and IBD: does everyone risk deficiency? Jimmy Limdi (Manchester)

14:40 Should thromboprophylaxis be extended after discharge in IBD? Vipul Jairath (Oxford)

15:00 Pain management in IBD Jane Quinlan (Oxford)

15:20 *Tea*

S4 Quality of care **Simon Travis/Ellie Barnes**

15:50 Lessons from psychiatry: the TrueColours programme John Geddes (Oxford)

16:10 Lessons from liver disease: cure for HCV comes closer Mark Wright (Southampton)

16:30 Creating change: the Karolinska initiative Michael Eberhardson (Stockholm)

16:50 Structured care pathways for IBD Subrata Ghosh (Calgary)

S5 Truelove Lecture

17:15 Stress and adaptation in immune-mediated disease Rick Blumberg (Boston)

18:00 Close

18:30 Pre-dinner drinks followed by dinner **Balliol College**

This meeting is supported by its delegates and unrestricted educational grants from the following companies who have had no input into the development or content of the meeting.

Major Sponsor: AbbVie; Platinum Sponsors: Gilead, Hospira, Janssen, Takeda, Vifor; Gold Sponsor: Ferring; Silver Sponsor: Perspectum Diagnostics

New Concepts and Care for IBD and Liver Disease

TUESDAY 30th SEPTEMBER

07:45 Registration, Examination Schools, Oxford

*Coffee***S6 Breakfast workshops**

08:15 Select from one of 8 workshops to discuss a topic in depth over coffee and croissants

New drugs for HCV	Jane Collier (Oxford)
IgG4, IBD and liver disease	Emma Culver (Oxford)
Biomarkers of inflammation and fibrosis	Kate Williamson (Oxford)
What's new in portal hypertension	John Ryan/Neil Rajoriya (Oxford)
Clinical trial design in IBD: pitfalls and pressures	Vipul Jairath (Oxford)
Managing dysplasia in IBD	James East/Elizabeth Bird-Lieberman (Oxford)
Complex perianal disease	Neil Mortensen (Oxford)
IBD in pregnancy	Lucy Mackillop/Becca Palmer (Oxford)

S7 Immune-mediated acute hepatitis**Paul Klenerman/Fiona Thompson**

09:00 Immune mediation of acute liver failure	Harry Antoniades (London)
09:25 Acute alcoholic hepatitis: the potential for immunomodulators	Debbie Shawcross (London)
09:50 Immunotherapy for HBV	Ellie Barnes (Oxford)

S8 Tackling NASH in the UK**Roger Chapman/Jeremy Tomlinson**

10:15 Non-invasive technologies to diagnose NASH	Michael Pavlides (Oxford)
10:35 NASH: underlying causes and strategies for prevention	Jeremy Cobbold (Oxford)

11:00 *Coffee***S9 Hepatocellular cancer****Jane Collier/Simon Leedham**

11:30 Finding the right treatment for the right patient with HCC	Markus Peck (Vienna)
11:55 Will antiviral therapy for HCV prevent HCC?	Geoffrey Dusheiko (London)
12:20 HCC and novel therapies	Helen Reeves (Newcastle)

12:45 *Lunch***S10 Novel interventions in Liver disease****Ellie Barnes/Jeremy Cobbold**

13:45 Clots in the liver: scarred for life?	Quentin Anstee (Newcastle)
14:10 Will STOPPAH stop what it is supposed to?	Mark Thursz (London)
14:35 Hepatitis head to head: therapeutic strategies for 2015	David Mutimer (Birmingham)
15:00 State of the Art: The management of PSC in 2020	Roger Chapman (Oxford)
15:30 Closing remarks & Tea	Simon Travis (Oxford)

This meeting is supported by its delegates and unrestricted educational grants from the following companies who have had no input into the development or content of the meeting.

Major Sponsor: AbbVie; Platinum Sponsors: Gilead, Hospira, Janssen, Takeda, Vifor; Gold Sponsor: Ferring; Silver Sponsor: Perspectum Diagnostics